RxDoctor Payments Data

David Thomas, MD

MOHS-Micrographic Surgery · Encintas, CANPI 1770515884

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.4% of the total across 172 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,755 and has fallen 88.0% since, to $211 in 2025.

$4,563in general payments, 2019–2025

Across 172 payments — averaging $26.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$923
  • Regeneron Healthcare Solutions, Inc.$593
  • Johnson & Johnson$388
  • Pfizer$376
  • LEO Pharma Inc.$267
  • Sun Pharmaceutical Industries Inc.$243
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$4,12490%
  • Education$43910%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,563 in reported general payments places this provider in the 65th percentile of 144 mohs-micrographic surgery providers in California.

See all mohs-micrographic surgery providers in California

Medicare billing

Part B allowed, 2024
$619,860
Medicare patients
891
Services billed
7,991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ivermectin18$2,358
Clobetasol Propionate43$2,064
Mupirocin158$1,046
Fluocinonide28$1,028
Metronidazole30$995
Fluorouracil12$813
Clindamycin Phosphate36$676
Triamcinolone Acetonide41$550
Desonide22$544
Imiquimod20$483
Doxycycline Hyclate47$478
Nystatin22$451
Ketoconazole22$431
Hydroxyzine Hcl12$266
Ciprofloxacin Hcl17$97

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in Encintas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →